(Q42182803)

English

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

multicenter clinical trial

0 references

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Willem P. Brouwer

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Adrian Streinu-Cercel

7

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Krzysztof Simon

12

object named as

Krzysztof Simon

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

18

object named as

Bettina E Hansen

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

author name string

Qing Xie

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Milan J Sonneveld

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Ningping Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Qin Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Fehmi Tabak

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Ji-Yao Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Ramazan Idilman

9

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hendrik W Reesink

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Mircea Diculescu

11

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Mihai Voiculescu

13

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Meral Akdogan

14

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Wlodzimierz Mazur

15

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Jurrien G P Reijnders

16

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Elke Verhey

17

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Harry L A Janssen

19

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

ARES Study Group

20

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

language of work or name

0 references

publication date

27 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

61

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

1512-1522

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

21 January 2018

Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27586

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.27586

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42182803&oldid=1590366144"